A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

I4T-MC-JVDL -

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Non-Small Cell Lung Cancer
What the trial is testing?
Ramucirumab, Osimertinib, Necitumumab
Could I receive a Placebo?
No
Enrollment Goal
29
Trial Dates
Oct 24, 2016 - May 9, 2022
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have a diagnosis of NSCLC with at least 1 measurable lesion

Participants Must Not:

  • Participant must not have had previous treatment with osimertinib or third generation EGFR TKIs

  • Participant must not have experienced a heart attack, unstable angina, or stroke, within 6 months prior to enrollment

  • Participant must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism during the 3 months prior to study enrollment

  • Participant must not have a bowel obstruction, Crohn's disease, ulcerative colitis, chronic diarrhea or a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment

  • Participant must not have uncontrolled hypertension

  • Participant must not be receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.